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Abstract 
Background: Mammalian microRNAs (miR) regulate the expression of genes relevant for the development of adap-
tive and innate immunity against cancer. Since T cell dysfunction has previously been reported in patients with renal 
cell carcinoma (RCC; clear cell type), we aimed to analyze these immune cells for genetic and protein differences 
when compared to normal donor T cells freshly after isolation and 35 days after in vitro stimulation (IVS) with HLA-
matched RCC tumor cells.
Methods: We investigated gene expression profiles of tumor-reactive CD8+ T cells obtained from RCC patient and 
compared with their HLA-matched healthy sibling donors using a microarray approach. In addition, miRNAs analysis 
was performed in a validation cohort of peripheral blood CD8+ T cells from 25 RCC patients compared to 15 healthy 
volunteers.
Results: We observed that CD8+ T cells from RCC patients expressed reduced levels of anti-apoptotic and prolifera-
tion-associated gene products when compared with normal donor T cells both pre- and post-IVS. In particular, JAK3 
and MCL-1 were down-regulated in patient CD8+ T cells versus their normal counterparts, likely due to defective 
suppressor activity of miR-29b and miR-198 in RCC CD8+ T cells. Indeed, specific inhibition of miR-29b or miR-198 in 
peripheral blood mononuclear cells (PBMCs) isolated from RCC patients, resulted in the up-regulation of JAK3 and 
MCL-1 proteins and significant improvement of cell survival in vitro.
Conclusions: Our results suggest that miR-29b and miR-198 dysregulation in RCC patient CD8+ T cells is associated 
with dysfunctional immunity and foreshadow the development of miR-targeted therapeutics to correct such T cell 
defects in vivo.
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Background
MicroRNAs (miRs) are 19- to 25-nucleotide non-coding 
RNA molecules that regulate gene expression at the level 
of transcription and translation by sequence-specific base 
pairing on the 3′ UTR of mRNA targets [1]. Findings over 
the past several years have revealed the important role of 
miRNAs in the regulation of crucial biological processes, 
including cell growth, differentiation, proliferation and 
apoptosis [2, 3]. More recently, numerous studies have 
demonstrated that miRNA profiles dictate the nature of 
adaptive and innate immunity, including controlling the 
differentiation of various immune cell subsets and their 
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has also been reported in the context of different types 
of human cancers [6] such as lung cancer [7], breast can-
cer [8], gastric cancer [9], and also renal cell carcinoma 
(RCC) [10, 11].
Clear-cell RCC is the most common type of kidney can-
cer, whose incidence rate has notably increased in recent 
years. RCC is perceived as an immunogenic tumor, in 
that spontaneous regression and/or objective clinical 
responses to immunotherapy have been observed in a 
minority of cases [12–14]. However, in the vast major-
ity of RCC patients, T cell responses are believed to be 
dysfunctional or “functionally inappropriate”, with many 
T effector cells noted to be in a pro-apoptotic state [15, 
16]. We reported that CD8+ T cells isolated from RCC 
patients exhibit defects in the JAK3/STAT5/6-signaling 
pathway, leading to T cell arrest in the G0/G1 phase of 
the cell cycle and prevention of their terminal differen-
tiation [17]. In the current study, we determined that 
JAK3 and MCL-1 expression is dysregulated in patient 
versus normal donor CD8+ T cells. MCL-1 is well known 
to be an anti-apoptotic member of the Bcl-2 family that 
promotes cell viability proliferation and differentiation 
[18, 19]. JAK3 is a non-receptor tyrosine kinase that has 
been implicated in the signal transduction of the com-
mon gamma chain subfamily of cytokine receptors. As a 
result, JAK3 plays an essential role in development, dif-
ferentiation, proliferation and survival of T-cells [20] and, 
as we have previously reported, JAK3 mutations are asso-
ciated with metastatic spread and poor survival of RCC 
patients [21].
Notably, we determined that MCL-1 and JAK3 expres-
sion levels in T cells were counter-regulated by miR-29b 
and miR-198, respectively, in RCC patients. These dis-
ease-associated miR alterations may hamper the effec-
tiveness of anti-tumor T cell responses and serve as 
biomarkers for T cell dysfunction in the cancer setting. 
Our data support the development of specific miR-tar-
geted therapeutics to resurrect/salvage anti-tumor T cell 
function in patients with RCC.
Methods
Patient samples
Peripheral blood mononuclear cells (PBMC) and well-
differentiated RCC of the clear cell type (showing 
prominent cytoplasmic clearing and thin-walled vascu-
lar channels) were obtained with written consent from 
25 patients treated with open radical nephrectomy or 
nephron-sparing surgery for clinically localized sporadic 
disease. Tumor cell cultures were established as previ-
ously described [22] using RPMI 1640 media supple-
mented with 2 mM l-glutamine 100 IU/ml penicillin and 
100  μg/ml streptomycin (Life Technologies, Inc. Grand 
Island, NY) and 20  % fetal bovine serum (FBS, Sigma). 
Based on its preferred growth characteristics, patient 
TC was selected and genotyped as HLA-A3, -A24, -B7, 
-B8 and Cw 7 (homozygous). The cloned RCC cell line 
developed from patient TC has been patented TC tumor-
derived cell line (ELTHEM —International patent PCT/
EP2006-067631: renal cell carcinoma cell line and use 
thereof ), and represents a highly-immunogenic cell line.
PBMCs and CD8+ T cells isolation
PBMCs were isolated at the interface of Ficoll-Hypaque 
density gradients after centrifugation (Sigma Chemi-
cal Co., St Louis, MO) from RCC patients and HLA-
matched healthy donors, following the manufacturer’s 
instructions. Cells were washed twice in PBS 1X (Invit-
rogen-Life Technologies, Italy) and used in mixed lym-
phocyte/tumor cell cultures as described below. HLA 
Class I typing was done using sequence-specific primed 
PCR (PCR-SSP) from genomic DNA (Dr. B. Favoino, Tis-
sue Typing Laboratory, Department of Clinical Pathol-
ogy II, Bari, Italy). HLA-matched normal donors were 
selected based on their sharing of single MHC class I 
alleles with the TC RCC cell line (Table 1). In particular, 
healthy donor 2 was a sibling donor. CD8+ T cells were 
isolated from the PBMCs of autologous and allogeneic 
normal, healthy donors by negative selection using spe-
cific MACS magnetic beads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) on MiniMACS columns, following 
the manufacturer’s protocol and subsequently assessed 
for their functional and phenotypic profiles.
Mixed lymphocyte/tumor cell cultures (MLTC)
MLTC experiments were performed as described in detail 
elsewhere (17,23). Briefly, PBMCs from RCC patients 
or HLA-matched healthy donors were co-cultured in 
24-well plates (Costar, Corning, USA) at 106 cells/well 
with irradiated RCC stimulator cells (105 cells/well) in 
AIM-V medium (Life Technologies, Invitrogen, Italy) 
supplemented with 10 % heat-inactivated pooled human 
serum [Sigma (medium Mb)]. Recombinant human IL-2 
was added on day 3 (250 IU/mL; Proleukin, Chiron, and 
Emeryville, CA). Responder lymphocytes were restimu-
lated weekly with 105 irradiated tumor cells in IL-2-con-
taining medium for 2  weeks prior to responder CD8+ 
T cells isolation. Positively isolated CD8+ T cells were 
Table 1 HLA-class I genotyping of  TC RCC and  healthy 
donor-2 and donor-3 PBMCs included in MLTC
HLA–A* HLA–B* HLA–C*
TC RCC 03:01 24:02 07:02 08:01 07:02 07:02
Donor-2 03:01 24:02 07:02 08:01 07:02 07:02
Donor-3 03:01 24:02 07:02 08:01 07:02 07:02
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cultured for an additional 2  weeks. On day 0 and day 
35 of culture, CD8+ T cells were analysed for gene and 
miRNA expression profiles.
Flow cytometry
One million freshly-isolated or day 35 cultured CD8+ T 
cells were washed twice with cold PBS 1× and double-
stained with Annexin V/7-AAD (Beckman Coulter). 
The cells were then analysed by a Beckman Coulter 
(FC500) flow cytometer. The same experiment was per-
formed on PBMC at 24 and 48 h after transfection with 
anti-hsa-miR-29b and anti-hsa-miR-198 and stained 
with Annexin V/propidium iodide (PI) (Beckman Coul-
ter). Apoptotic cells were considered as the sum of 
early and late apoptotic cells; early apoptotic cells are 
Annexin-V+/7-AAD– or IP−; late apoptotic cells are both 
Annexin-V+7/7-AAD+ or IP+; and necrotic cells were 
Annexin-V−/7-AAD+ or IP+. Jurkat T cells treated with 
dexamethasone 10−4 M for 24 h at 37 °C served as a posi-
tive control.
Microarray analysis and gene expression profiling
Total RNA was isolated from freshly-isolated and day 35 
cultured CD8+ T cells using Trizol© reagent (Life Tech-
nologies), according to the manufacturer’s instructions. 
Total RNA integrity was assessed by electrophoresis 
using the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, 
CA). Total RNA was processed and hybridized on to the 
GeneChip Human Genome U133A Array (Affymetrix, 
Santa Clara, CA), which contains 22,283 gene probe sets, 
representing approximately 12,000 well-characterized 
human genes (Affymetrix, Santa Clara, CA). For the sta-
tistical analysis, gene expression values for all gene probe 
sets, scaled to the target intensity of 2500, were log2 
transformed. Then, the analysis was carried out using the 
weighted average (WPGMA) method. Principal compo-
nent analysis (PCA) and 2-D hierarchical clustering were 
performed using Spotfire DecisionSite 8.1.1 (www.spot-
fire.com). Differentially expressed genes were identified 
using GeneSpring GX software (Agilent, Palo Alto, CA), 
by applying a moderated t test with Storey with boot-
strapping multiple testing correction. The fold change 
(FC) were obtained as ratio of normalized intensities 
between the average intensities of the samples grouped. 
To assess the relationship between genes, Ingenuity Path-
ways Analysis (IPA) (Ingenuity® Systems, www.ingenuity.
com), a software which constructs content rich relation-
ship networks between genes based on their connectiv-
ity according to information contained in the ingenuity 
pathways knowledge base, was applied. Results of the 
microarray experiments are available in Gene Expression 
Omnibus (Accession numbers: GSE6357).
Western blot validation of gene expression
CD8+ T cells were lysed with RIPA buffer (1  mM phe-
nylmethylsulphonylfluoride [PMSF], 5 mM EDTA, 1 mM 
sodium orthovanadate, 150  mM sodium chloride, 8  μg/
ml leupeptin, 1.5 % Nonidet P-40, 20 mM tris–HCl, pH 
7.4) and 40  μg of each lysate were separated by SDS-
PAGE and electroblotted onto a nitrocellulose filter. 
The filter was blocked overnight at RT with 10  % BSA 
in PBS containing 0.1 % Tween-20 (TBS) and incubated 
with anti-human JAK3 and anti-human MCL-1 Abs in 
5  % BSA-TBS (clones B-12 and B-6 respectively; 1:250 
dilution, Santa Cruz Biotechnology) overnight, at 4  °C. 
The membranes were washed in TBS-T 0.1 % and incu-
bated for 1  h at RT with horseradish-peroxidase-conju-
gated sheep anti-mouse IgG at 1:5000 dilution in TBS-T 
0.1 %. The membrane was then visualized using the ECL 
enhanced chemiluminescence system (Amersham, Lit-
tle Chalfont, UK). The same membranes were then 
immunoblotted again with anti-actin antibody (clone 
MM2/193; 1:2000 dilution; Santa Cruz Biotechnology). 
Signal detection and densitometric analysis of the bands 
was performed using a UVIchemi (UVItec, Cambridge) 
digital imaging system and UVI1D software (UVItec, 
Cambridge).
Reverse transcription and microRNA Real‑Time PCR 
quantification
CDNA was synthesized from total RNA of RCC 
CD8+ T cells using gene-specific primers according to 
theTaqMan MicroRNA assay protocol (PE Applied Bio-
systems, Foster City, CA). Reverse reactions for miR-
29b and miR-198 were performed using 10 ng of RNA 
samples, 50  nM stem-loop RT primers, 1× RT buffer, 
0.25 mM each of dNTPs, 3.33 U/μl multiscribe reverse 
transcriptase and 0.25  U/μl RNAse inhibitor (all pur-
chased from cDNA Archive kit of Applied Biosystems). 
Real-time PCR was performed using an Applied Biosys-
tems 7500 Fast Real-Time PCR system. The 10  μl PCR 
volume included 0.67  μl of RT product, 1× TaqMan 
universal PCR master mix and 1 μl of primers and probe 
mix of the Taq-Man MicroRNA assay (PE Applied Bio-
systems). Ct were determined using default threshold 
settings. miRNA let-7a was identified as the most sta-
ble housekeeping miRNA in lymphmonocytes and used 
to normalize the expression of each miRNA [24]. Rela-
tive quantification (RQ) of miRNA expression was cal-
culated with the 2-ΔΔCt method (Applied Biosystems 
User Bulletin N°2 [P/N 4303859]). Data are presented 
as relative quantity (RQ) of target miRNA, normalized 
with respect to miR-let-7a and a calibrator sample. As a 
calibrator, we used CD8+ T cells isolated from healthy 
normal donors.
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Anti‑miRNAs transfection
Anti-hsa-miR-198 miScript miRNA Inhibitor 
(MIN0000228) and Anti-hsa-miR-29b miScript miRNA 
Inhibitor (MIN0000100) were purchased from Qiagen 
(Hilden, Germany). miScript inhibitor negative control 
(Qiagen), which targets the sequence of AllStars nega-
tive control siRNA and has no homology to any known 
mammalian gene, was also used. PBMCs were seeded 
into 12-well plates at a density of 2 × 106 cells per well 
in 1 mL RPMI-1640 medium (Sigma-Aldrich) containing 
FBS (10 %) and Glutamine (1 %). Cells were transfected 
with 10–50–250  nM miRNA inhibitors using Oligo-
fectamine™ Transfection Reagent (Life Technologies), 
according to manufacturer’s instruction. After incubating 
the transfected cells for 24–48 h, western blotting analy-
sis for JAK3 and MCL-1 protein expression and apoptosis 
assay were performed as described above.
Statistical analysis
Data are reported as mean ±SD and analysed for dif-
ferences using an unpaired Student’s t test (Statview® 
software package, SAS Institute Inc. Cary, NC, USA). p 
values <0.05 were considered as significant.
Results
Tumor‑specific CD8+ T cell generation from RCC patient TC 
and allogenic HLA‑matched healthy donors
Tissue specimens were obtained from 30 patients under-
going radical or partial nephrectomy for unilateral renal 
cell carcinoma and primary tumor cells were established 
in vitro. The morphological features of the tumor tissues 
corresponded to well-differentiated renal cell carcinomas 
of the clear cell type, showing prominent cytoplasmic 
clearing and thin-walled vascular channels. Based on its 
preferred long-term in  vitro growth characteristics, the 
TC RCC cell line was selected for prospective use as a 
stimulator of T cell responses in  vitro. We selected two 
healthy donors with a complete HLA match to patient 
TC, with donor 2 representing a healthy sibling to patient 
TC. Using TC RCC cells, we stimulated autologous and 
two HLA-matched normal donor PBMCs in  vitro in 
mixed lymphocyte-tumor cell cultures (MLTC) as pre-
viously reported [17, 22, 23]. On day 21 after culture 
initiation, CD8+ T cells were isolated by negative immu-
nomagnetic cell separation and restimulated in an identi-
cal fashion (to the primary induction) for an additional 
2  weeks. On day 35 of culture, responder-CD8+ T cells 
from TC patient and normal donor cultures were evalu-
ated for gene expression profiles using microarray analy-
sis and the data compared with that obtained from the 
autologous, freshly-isolated CD8+ T cells (i.e. day 0 of 
culture). The CD8+ T cell isolated purity was evaluated 
by flow cytometry and ranged from 95 to 98 % (data not 
shown).
Analysis of gene expression differences between RCC 
patient TC and normal donor CD8+ T cells
Gene expression profiling was performed in triplicate on 
patient TC and 2 normal HLA-matched healthy donors. 
We separately analysed at day 0 and day 35 of MLTC, 
CD8+ T cell gene expression comparing TC patient 
versus normal donors and selected the differentially 
expressed genes in both comparisons using a q-value 
cut-off of 0.05. We then focused on the comparison at 
day 35 since MLTC was able to discern a gene expression 
pattern distinguishing naïve and activated CD8+ T cells 
from RCC patient and HLA-matched healthy donors. At 
day 0, we observed only a modest modulation of those 
processes which were subsequently investigated at day 
35. Unsupervised hierarchical clustering revealed that 
data derived from CD8+ T cells obtained from patient 
TC clustered differently versus CD8+ T cells from both 
normal donors (Fig.  1). Interestingly, genes included 
in the clusters B and H showed the best degree of dis-
crimination between CD8+ T cells isolated from patient 
TC and the two normal donors. Genes included in clus-
ter B (n = 391 genes) were down-regulated, while genes 
included in cluster H (n =  83 genes) were up-regulated 
compared to the healthy donors’ CD8+ T cells. To fur-
ther study the functions of genes differentially expressed, 
we performed an analysis by IPA (ingenuity pathways 
analysis) software. Interestingly, we observed that the top 
molecular and cellular functions in which the differen-
tial expressed genes were included, were cell death and 
survival (p value range 9.46*e-11 and 8.24*e-99) and cel-
lular growth and proliferation (p value range 9.75* e-11 
and 1.57*e-85). Among the genes involved in cell death 
and survival, we focused on those involved in apoptosis 
pathway (Additional file 1: Table S1). We found a signifi-
cant reduction of MCL-1 transcription factor (−1.34) in 
CD8+ T cells isolated from patient TC versus the normal 
donors. Additionally, we also observed that expression of 
the JAK3 gene product, which plays an essential role in 
haematopoiesis during T cell development, cell cycle and 
cell proliferation, was down-regulated (−1.44) in patient 
versus normal donor-derived CD8+ T cells.
JAK3 and MCL‑1 protein expression are reduced in CD8+ T 
cells isolated from RCC patient TC versus normal donors
MCL-1 and JAK3 were selected from the list of differ-
entially expressed genes based on their q-value, fold 
change and function. MCL-1 is an anti-apoptotic mem-
ber of the BCL-2 family, while JAK3 is known to play a 
crucial role in CD8+ T cell proliferation/differentiation 
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[25, 26] and its expression appears deficient in CD8+ T 
cells from RCC patients, leading to T cell arrest in cell 
cycle progression, as we previously described [17]. Thus, 
we next investigated MCL-1 and JAK3 protein expres-
sion in CD8+ T cells isolated from MLTC cultures on 
day 35 using western blot analysis. Consistent with the 
microarray results, JAK3 and MCL-1 protein levels were 
down-regulated in CD8+ T cells isolated from the TC 
RCC patient when compared to normal donor controls 
(Fig. 2a–b versus Fig. 2c–d respectively).
To evaluate the functional fate of CD8+ T cells isolated 
from RCC patient and healthy normal donors, we stained 
T cells for expression of Annexin-V/7-AAD and ana-
lysed these cells by flow cytometry. As shown in Fig.  3, 
we noted that CD8+ T cell from RCC patient TC on day 
0 exhibited a higher apoptotic rate when compared with 
T cells from the two normal donors (p < 0.003) and this 
data was exacerbated after 35 days of MLTC (p < 0.0001).
CD8+ T cells from RCC patient TC overexpress miR‑29b 
and miR‑198
In order to clarify the mechanism underlying CD8+ T 
cell dysfunction in RCC patients, we assessed whether 
differential expression of regulatory microRNA might 
influence MCL-1 and JAK3 gene expression. Accord-
ing to published data, we determined that miR-29b 
targets MCL-1 gene expression [27]. Moreover, data-
base information (PicTar: http://pictar.mdc-berlin.de, 
DIANA TOOLS: http://diana.imis.athena-innovation.
gr/DianaTools/index.php, PITA: http://omictools.com/
pita-s973.html) suggests that miR-198 may serve as 
regulators of JAK3 gene expression. Our analysis on 
freshly-isolated CD8+ T cells (day 0) indicated that 
both miR-29b and miR-198 expression were elevated 
in CD8+ T cells isolated from patient TC (Fig.  4a, b; 
p < 0.05 versus either normal donor). After 35 days of 
MLTC stimulation, patient T cell overexpression of 
Fig. 1 Gene expression profiling of responder CD8+ T cells using microarray analysis. Unsupervised hierarchical clustering of differentially expressed 
genes in CD8+ T cells isolated from RCC patient TC and 2 normal donors after 5 weeks of MLTC using RCC TC as a stimulus (day 35). Each column 
represents the average of normalised log intensity values for each triplicate determination. The triplicate was obtained by performing three inde-
pendent MTLC stimulations in parallel
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miR-29b (Fig. 4c; p < 0.005 versus either normal donor) 
and miR-198 (Fig.  4d; p  <  0.03 versus either normal 
donors) was maintained, and that of miR-29b was fur-
ther enhanced. miR16 was chosen as negative control 
miRNA, with no modulation of its expression observed 
between RCC patient and healthy donors (Fig. 4e, f ).
Peripheral blood CD8+ T cells from RCC patients display 
elevated expression of miR‑29b and miR‑198
The results obtained for RCC patient TC prompted us to 
investigate the generality of miR-29b and miR-198 over-
expression in a larger cohort of RCC patients (Table 2). 
CD8+ T cells were freshly isolated from the peripheral 
blood of 25 RCC patients and age matched-15 healthy 
normal donors. As shown in Fig.  5 (panels a and b), 
expression levels of both miR-29b and miR-198 were 
significantly up-regulated in RCC patients (p  <  0.02 
and p  <  0.01 respectively) when compared with normal 
donors. Furthermore, to evaluate whether the upregu-
lation of miR29b and miR198 in RCC patients was cor-
related to decreased MCL-1 and JAK3 gene levels, we 
monitored mRNA expression levels by qRT-PCR. As 
expected, we found that MCL-1 gene expression was 
significantly lower in RCC patients compared to healthy 
subjects (p  <  0.0001; Additional file  2: Figure S2). Simi-
larly, JAK3 gene expression was downregulated in RCC 
patients compared to controls but not so pronounced as 
MCL-1 trend (p < 0.005).
Inhibition of miR‑29b and miR‑198 enhance the 
expression of MCL‑1 and JAK3 and protects RCC PBMCs 
from apoptosis
To validate that miR-29b and miR-198 negatively regu-
late protein expression of MCL-1 and JAK3 in T cells, 
Fig. 2 RCC-reactive CD8+ T cells from patient TC exhibit reduced levels of Jak3 and MCL-1 proteins. Representative immunoblots are provided 
for d35-cultured CD8+ T cells isolated from patient TC versus normal donors using specific antibodies against total Jak3 (a) and MCL-1 (c) protein. 
Control antibodies recognizing actin are also provided. Relative levels of Jak3 and MCL-1 (both normalized to actin) are presented in panels b and 
d, respectively. Results in panels b and d are reported as the mean (±SD) of ratios obtained in three independent experiments. p < 0.005 for RCC vs 
donor 2; p < 0.0005 for RCC vs donor 3
(See figure on next page.) 
Fig. 3 CD8+ T cells isolated from RCC patient TC exhibit a sustained pro-apoptotic phenotype even after extended MLTC. Expression of Annexin-V 
by CD8+ T cells isolated from patient TC or normal donors pre- and post-MLTC culture is reported. Data represent the mean ±SD percentage of 
apoptotic cells determined from triplicate cultures using flow cytometry. Apoptotic cells were calculated as the sum of early and late apoptotic cells. 
These data were reproduced in three independent experiments. At day 0, TC CD8+ T cells showed an increase in apoptotic cells compared to donor 
2 and donor 3 (p < 0.0001 and p < 0.0001 by Student’s unpaired t-test). In vitro stimulation caused a slight decrease in apoptotic cell numbers in 
patient TC CD8+ T cells, but they were still higher than controls (p < 0.0035, p < 0.0001, respectively)
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transfection experiments were performed using their 
specific miRNA inhibitors: Anti-hsa-miR-29b and Anti-
hsa-miR-198. Given the high mortality rate observed 
after transfection of isolated CD8+ T cells, we decided to 
transfect total PBMCs and, as showed in Fig. 6 (panel a), 
the percentage of CD8+ T-lymphocytes ranged between 
30 and 45  % in PBMC samples from selected RCC 
patients. We selected those patients which expressed 
high miR-29b and miR-198 levels and freshly isolated 
PBMCs were transfected using Oligofectamine™ Trans-
fection Reagent with both Anti-hsa-miRNAs. As shown 
in Fig. 6 (panels b and c), silencing of miR-29b and miR-
198 for 48 h at 250 nM (no effects were observed at 24 h 
and at 10 and 50 nM), resulted in a marked induction of 
both protein levels when compared with scrambled miR 
control (p < 0.005 and p < 0.01, respectively).
Fig. 4 CD8+ T cells isolated from RCC patient TC express elevated levels of miR-29b and miR-198 when compared to normal donor T cells. Real-
time PCR analysis of mir-29b (panels a, b) and mir-198 (panels c, d) expression in CD8+ T cells from TC RCC and both HLA-matched normal donors, 
at day 0 (T0; panels a, c) and after 35 day of stimulation (T35; panels b, d). *p < 0.05 for RCC patient TC versus normal donors at T0. **p < 0.005 and 
*p < 0.03 for RCC patient TC versus normal donors at T35. Data are representative of 3 independent experiments performed. miR16 expression in 
CD8+ T cells from TC RCC and both HLA-matched normal donors at T0 (e) and T35 (f)
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To directly address miR-29b and miR-198 specificity 
and MCL-1 and JAK3′s involvement in tumor suppres-
sor activity, we investigated the effect of both miRNAs 
inhibition on apoptosis, as induction of immune cell 
apoptosis is a crucial event during malignant transforma-
tion. Interestingly, as shown in Fig. 7 (panels a and b), we 
Table 2 RCC patient and healthy donor demographics
RCC patients and healthy donors evaluated in the study. For RCC patients were considered age at time of surgery, sex, pathological stage, grade (Fuhrman), adjuvant 
treatment and at the last evaluation, follow-up months
Patient Age/sex Stage Grade Adjuvant treatment Healthy donor Age/sex
1 42 F T3aN0M0 2 – 1 41 M
2 53 M T1N0M0 3 – 2 50 M
3 60 M T3aN0M0 2 – 3 54 M
4 54 F T3aN0M0 2 – 4 52 F
5 68 M T3aN0M0 3 – 5 67 M
6 65 F T3aN0M0 3 – 6 60 F
7 65 F T3bN0M0 1 – 7 61 F
8 54 F T3aN0M0 3 – 8 50 F
9 67 M T3aN0M0 2 – 9 58 M
10 74 M T3bN0M0 2 – 10 72 M
11 53 M T1bN0M0 1 – 11 51 M
12 57 M T1aN0M0 2 – 12 57 M
13 63 F T1N0M0 1 – 13 53 F
14 80 F T1bN0M0 2 – 14 72 F
15 65 F T1aN0M0 2 – 15 61 F
16 72 M T1N1M0 2 –
17 64 F T2N1M0 2 –
18 43 M T1aN1M0 3 –
19 62 M T1bN0M0 1 –
20 33 M T3bN0M0 2 –
21 69 M T1aN0M0 2 –
22 72 M T3bN0M0 2 –
23 53 F T2N0M0 2 –
24 61 F T3aN0M0 3 –
25 60 M T3bN0M0 2 –
Fig. 5 Freshly-isolated CD8+ T cells from RCC patients exhibit elevated levels of miR-29b and miR-198 versus normal donors. CD8+ T cells were 
MACS-isolated from the PBMC of 25 primary RCC patients and 15 healthy normal donors. After extraction of RNA, quantitative RT-PCR was per-
formed for Mir-29b (panel a) and Mir-198 (panel b) as described in "Methods" section. Data are presented in box plots; *p < 0.05 for RCC patients 
versus healthy normal donors
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found that 48  h transfection with Anti-hsa-miRNA29b 
and Anti-hsa-miRNA198, rescued the cells from cell 
death and there was a significant reduction of cell apop-
tosis when compared with cells transfected with scram-
bled miR control, as measured by the Annexin V assay 
(p < 0.01 and p < 0.03, respectively).
Discussion
Over the past few years, the discovery of miRNAs has 
changed the landscape of human genetics and they 
have been widely studied in the field of oncology, where 
altered miRNA expression has been observed in a vari-
ety of human cancers [28]. Indeed, miRNA-expression 
profiling of human epithelial malignancies has led to 
the identification of signatures associated with diagno-
sis, staging, progression, prognosis and even response 
to treatment [29, 30]. However, few mechanistic studies 
have been carried out to dissect the functional role of 
miRNA in RCC, particularly in the context of “immune 
dysfunction” which may underlie disease progression. In 
fact, attaining effective tumor immunity is a major goal of 
the modern biologic therapy, limited by the tumor micro-
environment and regulatory mechanisms affecting T cell 
and NK cell effectors [31].
The major finding in this report is that CD8+ T 
cells isolated from RCC patients exhibit defects in 
Fig. 6 Transfection with specific Anti-hsa-miR inhibitors upregulate MCL-1 and JAK3 protein expression and rescues the cells from apoptosis. The 
percentage of CD8+ T cells in a freshly isolated PBMC sample is depicted from one RCC patient (a). PBMCs from RCC patients were transfected 
with 10, 50 and 250 nM Anti-hsa-miR-29b or Anti-hsa-miR-198 inhibitor and 10 and 250 nM scrambled miR control (SCR), as outlined in “Methods” 
section. After 48 h cell lysates were generated and western blots performed to quantitate MCL-1 (b) and JAK3 (c) protein levels. Three independent 
experiments were performed and gels showing MCL-1 and JAK3 protein levels were scanned and quantified. **p < 0.005 and *p < 0.01 versus cells 
only treated with 250 nM scrambled miR control
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proliferation and a propensity to undergo apoptotic cell 
death as a consequence of reduced expression of JAK3 
and MCL-1, the expression of which are regulated in vivo 
by tumor-induced upregulation of miRNAs miR198 and 
miR29b, respectively. To probe the clinical relevance 
of this hypothetical defect in antitumor T cell dysfunc-
tion amongst RCC patients, we investigated the genomic 
profile of tumor-reactive CD8+ T cells obtained after 
extended rounds of MLTC stimulation with an highly 
immunogenic RCC cell line (patient TC) and compared 
with their HLA-matched healthy donors (donor 2 and 3). 
Our results indicate that CD8+ T cells from patient TC 
cluster differently from normal donors and many of the 
genes differentially expressed were implicated in criti-
cal pathways, such as apoptosis, cell cycling and prolif-
eration. On the basis of the microarray data, we chose to 
focus on MCL-1 and JAK3 genes which appeared down-
regulated in tumor-reactive CD8+ T cells from RCC 
patient. JAK3 is a cytoplasmic tyrosine kinase and plays 
critical roles in cytokine signaling for development, dif-
ferentiation, proliferation and survival of T-cells. Deregu-
lation in JAK/STAT interaction promote tumorigenesis 
in haematological malignancies and epithelial tumors 
representing new therapeutic target [32, 33] and in our 
report we showed JAK3 mutations are associated with 
metastatic spread and poor survival of RCC patients 
[21]. MCL-1 is an anti-apoptotic member of the BCL-2 
family that is composed of both pro-apoptotic and anti-
apoptotic proteins, and the balance between these pro-
teins seems to determine life or death for the cell [34]. 
Bcl-2, MCL-1, and Bcl-Xl are anti-apoptotic proteins 
and promote cell survival and proliferation. Aberrant 
Fig. 7 Transfection with specific Anti-hsa-miR inhibitors upregulate MCL-1 and JAK3 protein expression and rescues the cells from apoptosis. 
Annexin V/PI assays in PBMCs after 48 h of transfection with Anti-hsa-miR-198 or Anti-hsa-miR-29b. Apoptotic cells were calculated as the sum of 
early and late apoptotic cells (a). The results are shown as percentage of apoptotic cells. Data are the average of six independent experiments ±SD, 
p < 0.01 and §p < 0.03 versus SCR (b)
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MCL-1 overexpression in numerous human cancers has 
been shown to result in increased proliferation, tumor 
cell survival, drug resistance and metastasis [35, 36]. On 
the other hand, coordinate down-regulation of MCL-1 
and JAK3 in T cells from RCC patients could represent a 
mechanism of immune evasion which confers a survival 
advantage to the tumor in the face of a muted attack by 
the immune system.
miRNAs regulate pro- and anti-apoptotic genes 
involved in programmed cell death pathways [37] and 
also play an important role in anti-tumor immunity by 
regulating the differentiation program of cytotoxic T 
lymphocytes (CTLs) [38]. The relevance of microRNAs in 
T cell immunity is highlighted by the finding that the lack 
of Dicer (a key enzyme for miRNA biogenesis) expression 
in CD8+ T cells results in impaired effector function(s) 
and differentiation [39]. Furthermore, a limited set of 
miRNA appears to regulate the differentiation program 
of CD8+ T cells following the priming of naïve cells into 
effector memory cells [40, 41]. However, the role of indi-
vidual miRNAs in the CD8+ T cell response has been 
only poorly explored to date. In the present study, we 
determined that MCL-1 and JAK3 expression levels in 
T cells are counter-regulated by miR-29b and miR-198, 
respectively. miR-29b has been shown to be amplified in 
various tumor types including myeloid leukemia [42, 43] 
and hepatocellular carcinoma [44], serving to promote 
tumorigenesis. This is the first report that investigates 
the expression and function of miR-29b and miR-198 in 
T cells from RCC patients. We observed that the high 
expression levels of these two miRNAs in CD8+ T cells 
could clearly discriminate CD8+ T cells freshly harvested 
from RCC patients versus normal donors. Notably, these 
molecular defects were retained in RCC patient TC even 
after extended rounds of MLTC stimulation, suggesting 
the need for sustained, targeted intervention if complete 
“normalization” of the RCC patient anti-tumor CD8+ T 
effector cell repertoire is desired as a (clinical) endpoint. 
Proof-of-principle may be suggested by our ability to res-
urrect MCL-1 and JAK3 expression in PBMCs from RCC 
patients upon transfection with anti-hsa-miR-29b and 
anti-hsa-miR-198 inhibitors. Our data confirm, as already 
demonstrated, that MCL-1 is a direct target of miR29b 
[27] and support the hypothesis that miR-198 directly or 
indirectly regulates JAK3 expression. Interestingly, the 
silencing of both miRNAs for 48 h resulted in improve-
ment of cell survival and protection from apoptosis.
It remains unclear what environmental cues provided 
by the tumor microenvironment in vivo or under condi-
tions of co-culture with tumor cells in vitro serve to sus-
tain elevated levels of regulatory miRs such as miR29b 
and miR198 in RCC patient T cells. Conversely, will 
therapies known to enhance the anti-tumor immunity 
(i.e. IFN-alpha, sunitinib, etc.) suppress expression of 
these miRs in patient T cells in  vivo? These are major 
questions that warrant prospective studies in order to 
further elucidate and counter—act the pro-tumor impact 
of miRs on protective host immunity, thereby optimizing 
the therapeutic potential of anti-tumor CD8+ T effector 
cells.
Conclusion
CD8+ T cells isolated from RCC patients exhibit defects 
in proliferation and a propensity to undergo apoptotic 
cell death as a consequence of reduced expression of 
JAK3 and MCL-1 that are regulated in  vivo by overex-
pressed miRNAs miR198 and miR29b, respectively.
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